Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolterodine and Pregabalin for Overactive Bladder
NCT00746681Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of pregabalin in overactive bladder (OAB) (5 arms), sponsored by Pfizer. Primary endpoint: Change in mean voided volume per micturition at 4 weeks. Started Dec 2005; status: completed.
02
Drugs
pregabalin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00746681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00746681.